Across TCGA pan-cancer cohorts, TRGJP2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated TRGJP2 data layer.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TRGJP2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated TRGJP2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and CESC show a favorable association.
BLCA, CESC, and DLBC are the cancer types where TRGJP2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.